You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer

Citation Tools

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Mirza MR, O’Malley DM, Harter P, et al
2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer
International Journal of Gynecologic Cancer 2022;32:A234.